Global Acute Myeloid Leukaemia Therapeutics Supply, Demand and Key Producers, 2023-2029
The global Acute Myeloid Leukaemia Therapeutics market size is expected to reach $ 7125.8 million by 2029, rising at a market growth of 10.2% CAGR during the forecast period (2023-2029).
This report studies the global Acute Myeloid Leukaemia Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Acute Myeloid Leukaemia Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Acute Myeloid Leukaemia Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Acute Myeloid Leukaemia Therapeutics total market, 2018-2029, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Acute Myeloid Leukaemia Therapeutics total market, key domestic companies and share, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Acute Myeloid Leukaemia Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Acute Myeloid Leukaemia Therapeutics market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Acute Myeloid Leukaemia Therapeutics Market, By Region:
1. How big is the global Acute Myeloid Leukaemia Therapeutics market?
2. What is the demand of the global Acute Myeloid Leukaemia Therapeutics market?
3. What is the year over year growth of the global Acute Myeloid Leukaemia Therapeutics market?
4. What is the total value of the global Acute Myeloid Leukaemia Therapeutics market?
5. Who are the major players in the global Acute Myeloid Leukaemia Therapeutics market?
This report studies the global Acute Myeloid Leukaemia Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Acute Myeloid Leukaemia Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Acute Myeloid Leukaemia Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Acute Myeloid Leukaemia Therapeutics total market, 2018-2029, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Acute Myeloid Leukaemia Therapeutics total market, key domestic companies and share, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Acute Myeloid Leukaemia Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Acute Myeloid Leukaemia Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Acute Myeloid Leukaemia Therapeutics market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Acute Myeloid Leukaemia Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hypomethylating Agents
- Others
- Specialty Clinics
- Hospital
- Others
- Pfizer Inc.
- Novartis AG
- Celgene Corporation
- Astellas Pharma Inc.
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals
- Boehringer Ingelheim International GmbH
- Johnson & Johnson
- Gilead Sciences, Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Sunesis Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc.
1. How big is the global Acute Myeloid Leukaemia Therapeutics market?
2. What is the demand of the global Acute Myeloid Leukaemia Therapeutics market?
3. What is the year over year growth of the global Acute Myeloid Leukaemia Therapeutics market?
4. What is the total value of the global Acute Myeloid Leukaemia Therapeutics market?
5. Who are the major players in the global Acute Myeloid Leukaemia Therapeutics market?
1 SUPPLY SUMMARY
1.1 Acute Myeloid Leukaemia Therapeutics Introduction
1.2 World Acute Myeloid Leukaemia Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Acute Myeloid Leukaemia Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.3 China Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.5 Japan Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.6 South Korea Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.8 India Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Acute Myeloid Leukaemia Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Acute Myeloid Leukaemia Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.2 World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region
2.2.1 World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.4 China Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.5 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.6 Japan Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.7 South Korea Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.9 India Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
3 WORLD ACUTE MYELOID LEUKAEMIA THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Acute Myeloid Leukaemia Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Acute Myeloid Leukaemia Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Acute Myeloid Leukaemia Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Acute Myeloid Leukaemia Therapeutics in 2022
3.3 Acute Myeloid Leukaemia Therapeutics Company Evaluation Quadrant
3.4 Acute Myeloid Leukaemia Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Acute Myeloid Leukaemia Therapeutics Market: Region Footprint
3.4.2 Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
3.4.3 Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Acute Myeloid Leukaemia Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Acute Myeloid Leukaemia Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Acute Myeloid Leukaemia Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Immunotherapy
5.2.4 Hypomethylating Agents
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2018-2023)
5.3.2 World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2024-2029)
5.3.3 World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Acute Myeloid Leukaemia Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Specialty Clinics
6.2.2 Hospital
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2023)
6.3.2 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2024-2029)
6.3.3 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Details
7.1.2 Pfizer Inc. Major Business
7.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer Inc. Recent Developments/Updates
7.1.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.2 Novartis AG
7.2.1 Novartis AG Details
7.2.2 Novartis AG Major Business
7.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Services
7.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis AG Recent Developments/Updates
7.2.6 Novartis AG Competitive Strengths & Weaknesses
7.3 Celgene Corporation
7.3.1 Celgene Corporation Details
7.3.2 Celgene Corporation Major Business
7.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Services
7.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Celgene Corporation Recent Developments/Updates
7.3.6 Celgene Corporation Competitive Strengths & Weaknesses
7.4 Astellas Pharma Inc.
7.4.1 Astellas Pharma Inc. Details
7.4.2 Astellas Pharma Inc. Major Business
7.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Astellas Pharma Inc. Recent Developments/Updates
7.4.6 Astellas Pharma Inc. Competitive Strengths & Weaknesses
7.5 Daiichi Sankyo Company, Limited
7.5.1 Daiichi Sankyo Company, Limited Details
7.5.2 Daiichi Sankyo Company, Limited Major Business
7.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Services
7.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
7.5.6 Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
7.6 Jazz Pharmaceuticals
7.6.1 Jazz Pharmaceuticals Details
7.6.2 Jazz Pharmaceuticals Major Business
7.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Services
7.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Jazz Pharmaceuticals Recent Developments/Updates
7.6.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Boehringer Ingelheim International GmbH
7.7.1 Boehringer Ingelheim International GmbH Details
7.7.2 Boehringer Ingelheim International GmbH Major Business
7.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Services
7.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
7.7.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
7.8 Johnson & Johnson
7.8.1 Johnson & Johnson Details
7.8.2 Johnson & Johnson Major Business
7.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Services
7.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Johnson & Johnson Recent Developments/Updates
7.8.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.9 Gilead Sciences, Inc.
7.9.1 Gilead Sciences, Inc. Details
7.9.2 Gilead Sciences, Inc. Major Business
7.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Gilead Sciences, Inc. Recent Developments/Updates
7.9.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.10 Amgen Inc.
7.10.1 Amgen Inc. Details
7.10.2 Amgen Inc. Major Business
7.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Amgen Inc. Recent Developments/Updates
7.10.6 Amgen Inc. Competitive Strengths & Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Takeda Pharmaceutical Company Limited Details
7.11.2 Takeda Pharmaceutical Company Limited Major Business
7.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Services
7.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7.11.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
7.12 Sunesis Pharmaceuticals, Inc.
7.12.1 Sunesis Pharmaceuticals, Inc. Details
7.12.2 Sunesis Pharmaceuticals, Inc. Major Business
7.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments/Updates
7.12.6 Sunesis Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.13 Agios Pharmaceuticals, Inc.
7.13.1 Agios Pharmaceuticals, Inc. Details
7.13.2 Agios Pharmaceuticals, Inc. Major Business
7.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Agios Pharmaceuticals, Inc. Recent Developments/Updates
7.13.6 Agios Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Acute Myeloid Leukaemia Therapeutics Industry Chain
8.2 Acute Myeloid Leukaemia Therapeutics Upstream Analysis
8.3 Acute Myeloid Leukaemia Therapeutics Midstream Analysis
8.4 Acute Myeloid Leukaemia Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Acute Myeloid Leukaemia Therapeutics Introduction
1.2 World Acute Myeloid Leukaemia Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Acute Myeloid Leukaemia Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.3 China Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.5 Japan Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.6 South Korea Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.3.8 India Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Acute Myeloid Leukaemia Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Acute Myeloid Leukaemia Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.2 World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region
2.2.1 World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.4 China Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.5 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.6 Japan Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.7 South Korea Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
2.9 India Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029)
3 WORLD ACUTE MYELOID LEUKAEMIA THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Acute Myeloid Leukaemia Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Acute Myeloid Leukaemia Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Acute Myeloid Leukaemia Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Acute Myeloid Leukaemia Therapeutics in 2022
3.3 Acute Myeloid Leukaemia Therapeutics Company Evaluation Quadrant
3.4 Acute Myeloid Leukaemia Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Acute Myeloid Leukaemia Therapeutics Market: Region Footprint
3.4.2 Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
3.4.3 Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Acute Myeloid Leukaemia Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Acute Myeloid Leukaemia Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Acute Myeloid Leukaemia Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Immunotherapy
5.2.4 Hypomethylating Agents
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2018-2023)
5.3.2 World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2024-2029)
5.3.3 World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Acute Myeloid Leukaemia Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Specialty Clinics
6.2.2 Hospital
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2023)
6.3.2 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2024-2029)
6.3.3 World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Details
7.1.2 Pfizer Inc. Major Business
7.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer Inc. Recent Developments/Updates
7.1.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.2 Novartis AG
7.2.1 Novartis AG Details
7.2.2 Novartis AG Major Business
7.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Services
7.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis AG Recent Developments/Updates
7.2.6 Novartis AG Competitive Strengths & Weaknesses
7.3 Celgene Corporation
7.3.1 Celgene Corporation Details
7.3.2 Celgene Corporation Major Business
7.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Services
7.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Celgene Corporation Recent Developments/Updates
7.3.6 Celgene Corporation Competitive Strengths & Weaknesses
7.4 Astellas Pharma Inc.
7.4.1 Astellas Pharma Inc. Details
7.4.2 Astellas Pharma Inc. Major Business
7.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Astellas Pharma Inc. Recent Developments/Updates
7.4.6 Astellas Pharma Inc. Competitive Strengths & Weaknesses
7.5 Daiichi Sankyo Company, Limited
7.5.1 Daiichi Sankyo Company, Limited Details
7.5.2 Daiichi Sankyo Company, Limited Major Business
7.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Services
7.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
7.5.6 Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
7.6 Jazz Pharmaceuticals
7.6.1 Jazz Pharmaceuticals Details
7.6.2 Jazz Pharmaceuticals Major Business
7.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Services
7.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Jazz Pharmaceuticals Recent Developments/Updates
7.6.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Boehringer Ingelheim International GmbH
7.7.1 Boehringer Ingelheim International GmbH Details
7.7.2 Boehringer Ingelheim International GmbH Major Business
7.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Services
7.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
7.7.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
7.8 Johnson & Johnson
7.8.1 Johnson & Johnson Details
7.8.2 Johnson & Johnson Major Business
7.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Services
7.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Johnson & Johnson Recent Developments/Updates
7.8.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.9 Gilead Sciences, Inc.
7.9.1 Gilead Sciences, Inc. Details
7.9.2 Gilead Sciences, Inc. Major Business
7.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Gilead Sciences, Inc. Recent Developments/Updates
7.9.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.10 Amgen Inc.
7.10.1 Amgen Inc. Details
7.10.2 Amgen Inc. Major Business
7.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Amgen Inc. Recent Developments/Updates
7.10.6 Amgen Inc. Competitive Strengths & Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Takeda Pharmaceutical Company Limited Details
7.11.2 Takeda Pharmaceutical Company Limited Major Business
7.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Services
7.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7.11.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
7.12 Sunesis Pharmaceuticals, Inc.
7.12.1 Sunesis Pharmaceuticals, Inc. Details
7.12.2 Sunesis Pharmaceuticals, Inc. Major Business
7.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments/Updates
7.12.6 Sunesis Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.13 Agios Pharmaceuticals, Inc.
7.13.1 Agios Pharmaceuticals, Inc. Details
7.13.2 Agios Pharmaceuticals, Inc. Major Business
7.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
7.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Agios Pharmaceuticals, Inc. Recent Developments/Updates
7.13.6 Agios Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Acute Myeloid Leukaemia Therapeutics Industry Chain
8.2 Acute Myeloid Leukaemia Therapeutics Upstream Analysis
8.3 Acute Myeloid Leukaemia Therapeutics Midstream Analysis
8.4 Acute Myeloid Leukaemia Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Acute Myeloid Leukaemia Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Acute Myeloid Leukaemia Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Acute Myeloid Leukaemia Therapeutics Players in 2022
Table 12. World Acute Myeloid Leukaemia Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Acute Myeloid Leukaemia Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Acute Myeloid Leukaemia Therapeutics Player
Table 15. Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
Table 16. Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
Table 17. Acute Myeloid Leukaemia Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Acute Myeloid Leukaemia Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 29. World Acute Myeloid Leukaemia Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Acute Myeloid Leukaemia Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Pfizer Inc. Basic Information, Area Served and Competitors
Table 36. Pfizer Inc. Major Business
Table 37. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 38. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Pfizer Inc. Recent Developments/Updates
Table 40. Pfizer Inc. Competitive Strengths & Weaknesses
Table 41. Novartis AG Basic Information, Area Served and Competitors
Table 42. Novartis AG Major Business
Table 43. Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Services
Table 44. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis AG Recent Developments/Updates
Table 46. Novartis AG Competitive Strengths & Weaknesses
Table 47. Celgene Corporation Basic Information, Area Served and Competitors
Table 48. Celgene Corporation Major Business
Table 49. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Services
Table 50. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Celgene Corporation Recent Developments/Updates
Table 52. Celgene Corporation Competitive Strengths & Weaknesses
Table 53. Astellas Pharma Inc. Basic Information, Area Served and Competitors
Table 54. Astellas Pharma Inc. Major Business
Table 55. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 56. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Astellas Pharma Inc. Recent Developments/Updates
Table 58. Astellas Pharma Inc. Competitive Strengths & Weaknesses
Table 59. Daiichi Sankyo Company, Limited Basic Information, Area Served and Competitors
Table 60. Daiichi Sankyo Company, Limited Major Business
Table 61. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Services
Table 62. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 64. Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
Table 65. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Jazz Pharmaceuticals Major Business
Table 67. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Services
Table 68. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Jazz Pharmaceuticals Recent Developments/Updates
Table 70. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Boehringer Ingelheim International GmbH Basic Information, Area Served and Competitors
Table 72. Boehringer Ingelheim International GmbH Major Business
Table 73. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Services
Table 74. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 76. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
Table 77. Johnson & Johnson Basic Information, Area Served and Competitors
Table 78. Johnson & Johnson Major Business
Table 79. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Services
Table 80. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Johnson & Johnson Recent Developments/Updates
Table 82. Johnson & Johnson Competitive Strengths & Weaknesses
Table 83. Gilead Sciences, Inc. Basic Information, Area Served and Competitors
Table 84. Gilead Sciences, Inc. Major Business
Table 85. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 86. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Gilead Sciences, Inc. Recent Developments/Updates
Table 88. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 89. Amgen Inc. Basic Information, Area Served and Competitors
Table 90. Amgen Inc. Major Business
Table 91. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 92. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Amgen Inc. Recent Developments/Updates
Table 94. Amgen Inc. Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Services
Table 98. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 101. Sunesis Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 102. Sunesis Pharmaceuticals, Inc. Major Business
Table 103. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 104. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Sunesis Pharmaceuticals, Inc. Recent Developments/Updates
Table 106. Agios Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 107. Agios Pharmaceuticals, Inc. Major Business
Table 108. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 109. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 110. Global Key Players of Acute Myeloid Leukaemia Therapeutics Upstream (Raw Materials)
Table 111. Acute Myeloid Leukaemia Therapeutics Typical Customers
List of Figure
Figure 1. Acute Myeloid Leukaemia Therapeutics Picture
Figure 2. World Acute Myeloid Leukaemia Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Acute Myeloid Leukaemia Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Acute Myeloid Leukaemia Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Acute Myeloid Leukaemia Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Acute Myeloid Leukaemia Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Acute Myeloid Leukaemia Therapeutics Markets in 2022
Figure 27. United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Acute Myeloid Leukaemia Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type in 2022
Figure 31. Chemotherapy
Figure 32. Targeted Therapy
Figure 33. Immunotherapy
Figure 34. Hypomethylating Agents
Figure 35. Others
Figure 36. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type (2018-2029)
Figure 37. World Acute Myeloid Leukaemia Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 38. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Application in 2022
Figure 39. Specialty Clinics
Figure 40. Hospital
Figure 41. Others
Figure 42. Acute Myeloid Leukaemia Therapeutics Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
Table 1. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Acute Myeloid Leukaemia Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Acute Myeloid Leukaemia Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Acute Myeloid Leukaemia Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Acute Myeloid Leukaemia Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Acute Myeloid Leukaemia Therapeutics Players in 2022
Table 12. World Acute Myeloid Leukaemia Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Acute Myeloid Leukaemia Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Acute Myeloid Leukaemia Therapeutics Player
Table 15. Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
Table 16. Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
Table 17. Acute Myeloid Leukaemia Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Acute Myeloid Leukaemia Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Acute Myeloid Leukaemia Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Acute Myeloid Leukaemia Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Acute Myeloid Leukaemia Therapeutics Revenue Market Share (2018-2023)
Table 29. World Acute Myeloid Leukaemia Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Acute Myeloid Leukaemia Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Acute Myeloid Leukaemia Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Acute Myeloid Leukaemia Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Pfizer Inc. Basic Information, Area Served and Competitors
Table 36. Pfizer Inc. Major Business
Table 37. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 38. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Pfizer Inc. Recent Developments/Updates
Table 40. Pfizer Inc. Competitive Strengths & Weaknesses
Table 41. Novartis AG Basic Information, Area Served and Competitors
Table 42. Novartis AG Major Business
Table 43. Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Services
Table 44. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis AG Recent Developments/Updates
Table 46. Novartis AG Competitive Strengths & Weaknesses
Table 47. Celgene Corporation Basic Information, Area Served and Competitors
Table 48. Celgene Corporation Major Business
Table 49. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Services
Table 50. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Celgene Corporation Recent Developments/Updates
Table 52. Celgene Corporation Competitive Strengths & Weaknesses
Table 53. Astellas Pharma Inc. Basic Information, Area Served and Competitors
Table 54. Astellas Pharma Inc. Major Business
Table 55. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 56. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Astellas Pharma Inc. Recent Developments/Updates
Table 58. Astellas Pharma Inc. Competitive Strengths & Weaknesses
Table 59. Daiichi Sankyo Company, Limited Basic Information, Area Served and Competitors
Table 60. Daiichi Sankyo Company, Limited Major Business
Table 61. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Services
Table 62. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 64. Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
Table 65. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Jazz Pharmaceuticals Major Business
Table 67. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Services
Table 68. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Jazz Pharmaceuticals Recent Developments/Updates
Table 70. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Boehringer Ingelheim International GmbH Basic Information, Area Served and Competitors
Table 72. Boehringer Ingelheim International GmbH Major Business
Table 73. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Services
Table 74. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 76. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
Table 77. Johnson & Johnson Basic Information, Area Served and Competitors
Table 78. Johnson & Johnson Major Business
Table 79. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Services
Table 80. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Johnson & Johnson Recent Developments/Updates
Table 82. Johnson & Johnson Competitive Strengths & Weaknesses
Table 83. Gilead Sciences, Inc. Basic Information, Area Served and Competitors
Table 84. Gilead Sciences, Inc. Major Business
Table 85. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 86. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Gilead Sciences, Inc. Recent Developments/Updates
Table 88. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 89. Amgen Inc. Basic Information, Area Served and Competitors
Table 90. Amgen Inc. Major Business
Table 91. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 92. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Amgen Inc. Recent Developments/Updates
Table 94. Amgen Inc. Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Services
Table 98. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 101. Sunesis Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 102. Sunesis Pharmaceuticals, Inc. Major Business
Table 103. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 104. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Sunesis Pharmaceuticals, Inc. Recent Developments/Updates
Table 106. Agios Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 107. Agios Pharmaceuticals, Inc. Major Business
Table 108. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Services
Table 109. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 110. Global Key Players of Acute Myeloid Leukaemia Therapeutics Upstream (Raw Materials)
Table 111. Acute Myeloid Leukaemia Therapeutics Typical Customers
List of Figure
Figure 1. Acute Myeloid Leukaemia Therapeutics Picture
Figure 2. World Acute Myeloid Leukaemia Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Acute Myeloid Leukaemia Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Acute Myeloid Leukaemia Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Acute Myeloid Leukaemia Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Acute Myeloid Leukaemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Acute Myeloid Leukaemia Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Acute Myeloid Leukaemia Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Acute Myeloid Leukaemia Therapeutics Markets in 2022
Figure 27. United States VS China: Acute Myeloid Leukaemia Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Acute Myeloid Leukaemia Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type in 2022
Figure 31. Chemotherapy
Figure 32. Targeted Therapy
Figure 33. Immunotherapy
Figure 34. Hypomethylating Agents
Figure 35. Others
Figure 36. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type (2018-2029)
Figure 37. World Acute Myeloid Leukaemia Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 38. World Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Application in 2022
Figure 39. Specialty Clinics
Figure 40. Hospital
Figure 41. Others
Figure 42. Acute Myeloid Leukaemia Therapeutics Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
